Bayawa, Peter .
HRN: 26-16-36 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/02/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
11/02/2024
11/09/2024
IV
2.25g
Q6h
Nonhealing Wound, R Foot
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes